HIV infection and periodontal diseases: An overview of the post-HAART era

Oral Diseases

Volumn 17, Issue 1, 2011, Pages 13-25

  Mataftsi, M ^a   Skoura, L ^b   Sakellari, D ^c  

^a Private Practice   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Highly active antiretroviral therapy; HIV; Periodontitis

Indexed keywords

ANTIRETROVIRUS AGENT; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

DISEASE ASSOCIATION; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR GINGIVITIS ERYTHEMA; MICROBIAL COLONIZATION; MOUTH FLORA; NECROTIZING ULCERATIVE PERIODONTITIS; PERIODONTAL DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; THRUSH; VINCENT STOMATITIS; VIRUS CELL INTERACTION; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; OPPORTUNISTIC INFECTIONS; PERIODONTAL DISEASES;

EID: 78650138828     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2010.01727.x     Document Type: Review

References (126)

1. Aas JA, Barbuto SM, Alpagot T, Olsen I, Dewhirst FE, Paster BJ (2007). Subgingival plaque microbiota in HIV positive patients. J Clin Periodontol 34: 189-195.
2. Aguirre JM, Echebarria MA, Ocina E, Ribacoba L, Montejo M (1999). Reduction of HIV-associated oral lesions after highly active antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88: 114-115.
3. Alpagot T, Font K, Lee A (2003). Longitudinal evaluation of GCF IFN-gamma levels and periodontal status in HIV+ patients. J Clin Periodontol 30: 944-948.
4. Alpagot T, Duzgunes N, Wolff LF, Lee A (2004). Risk factors for periodontitis in HIV patients. J Periodontal Res 39: 149-157.
5. Aquino-García SI, Rivas MA, Ceballos-Salobreña A, Acosta-Gio AE, Gaitán-Cepeda LA (2008). Short communication: oral lesions in HIV/AIDS patients undergoing HAART including efavirenz. AIDS Res Hum Retroviruses 24: 815-820.
6. Armitage GC (1999). Development of a classification system for periodontal diseases and conditions. Ann Periodontol 4: 1-6.
7. Baron S, Poast J, Cloyd MW (1999). Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. Arch Intern Med 159: 303-310.
8. Barr C, Lopez MR, Rua-Dobles A (1992). Periodontal changes by HIV serostatus in a cohort of homosexual and bisexual men. J Clin Periodontol 19: 794-801.
9. Begg MD, Panageas KS, Mitchell-Lewis D, Bucklan RS, Phelan JA, Lamster IB (1996). Oral lesions as markers of severe immunosuppression in HIV-infected homosexual men and injection drug users. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82: 276-283.
10. Bolscher JG, Nazmi K, Ran LJ et al (2002). Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva. Eur J Oral Sci 110: 149-156.
11. Botero JE, Contreras A, Lafaurie G, Jaramillo A, Betancourt M, Arce RM (2007). Occurrence of periodontopathic and superinfecting bacteria in chronic and aggressive periodontitis subjects in a Colombian population. J Periodontol 78: 696-704.
12. Brady LJ, Walker C, Oxford GE, Stewart C, Magnusson I, McArthur W (1996). Oral diseases, mycology and periodontal microbiology of HIV-1-infected women. Oral Microbiol Immunol 11: 371-380.
13. Bravo IM, Correnti M, Escalona L et al (2006). Prevalence of oral lesions in HIV patients related to CD4 cell count and viral load in a Venezuelan population. Med Oral Patol Oral Cir Bucal 11: E33-E39.
14. CDC (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41: 1-19.
15. Ceballos-Salobreña A, Aguirre-Urizar JM, Bagan-Sebastian JV (1996). Oral manifestations associated with human immunodeficiency virus infection in a Spanish population. J Oral Pathol Med 25: 523-526.
16. Ceballos-Salobreña A, Gaitán-Cepeda LA, Ceballos-Garcia L, Lezama-Del Valle D (2000). Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDS 14: 627-635.
17. Challacombe SJ, Naglik JR (2006). The effects of HIV infection on oral mucosal immunity. Adv Dent Res 19: 29-35.
18. Chebbi F, Poveda JD, Suzuki T et al (1997). Search for infectious HIV in gingival crevicular fluid and saliva of advanced AIDS patients with severe periodontitis. AIDS 11: 927-928.
19. Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS (1999). Re-emergence of HIV after stopping therapy. Nature 401: 874-875.
20. Cohen MS, Shugars DC, Fiscus SA (2000). Limits on oral transmission of HIV 1: Lancet-356.
21. Colin L, Van Lint C (2009). Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6: 111, Doi: .
22. Coogan MM, Greenspan J, Challacombe SJ (2005). Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ 83: 700-706.
23. Cross DL, Smith GL (1995). Comparison of periodontal disease in HIV seropositive subjects and controls (II). Microbiology, immunology and predictors of disease progression. J Clin Periodontol 22: 569-577.
24. Crum-Cianflone NF (2006). Immune reconstitution inflammatory syndromes: what's new? AIDS Read 16: 199-206.
25. Cutler CW, Jotwani R (2006). Oral mucosal expression of HIV-1 receptors, co-receptors, and alpha-defensins: tableau of resistance or susceptibility to HIV infection? Adv Dent Res 19: 49-51.
26. Dahl V, Josefsson L, Palmer S (2009). HIV reservoirs, latency, and reactivation: Prospects for eradication. Antiviral Res 85: 286-294.
27. Dale BA (2002). Periodontal epithelium: a newly recognized role in health and disease. Periodontol 2000(30): 70-78.
28. Dutzan N, Vernal R, Hernandez M et al (2009). Levels of interferon-gamma and transcription factor T-bet in progressive periodontal lesions in patients with chronic periodontitis. J Periodontol 80: 290-296.
29. EC-Clearinghouse (1993). EC-Clearinghouse on oral problems related to HIV infection and WHO collaborating centre on oral manifestations of the immunodeficiency virus classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 22: 289-291.
30. Eyeson JD, Tenant-Flowers M, Cooper DJ, Johnson NW, Warnakulasuriya KA (2002). Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London. J Oral Pathol Med 31: 169-174.
31. Fellay J, Boubaker K, Ledergerber B et al; Swiss HIV Cohort Study (2001). Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358: 1322-1327.
32. Feller L, Wood N, Lemmer J (2007). Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104: 455-460.
33. Ferreira S, Noce C, Júnior AS et al (2007). Prevalence of oral manifestations of HIV infection in Rio De Janeiro, Brazil from 1988 to 2004. AIDS Patient Care STDS 21: 724-731.
34. Flanagan MA, Barasch A, Koenigsberg SR, Fine D, Houpt M (2000). Prevalence of oral soft tissue lesions in HIV-infected minority children treated with highly active antiretroviral therapies. Pediatr Dent 22: 287-291.
35. Flint SR, Tappuni A, Leigh J, Schmidt-Westhausen AM, MacPhail L (2006). (B3)Markers of immunodeficiency and mechanisms of HAART therapy on oral lesions. Adv Dent Res 19: 146-151.
36. Gaitan Cepeda LA, Ceballos Salobreña A, López Ortega K, Arzate Mora N, Jiménez Soriano Y (2008). Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy. Epidemiological evidence. Med Oral Pathol Oral Cir Bucal 13: E85-E93.
37. Gaitán-Cepeda L, Cashat-Cruz M, Morales-Aguirre JJ et al (2002). Prevalence of oral lesions in Mexican children with perinatally acquired HIV: association with immunologic status, viral load, and gender. AIDS Patient Care STDS 16: 151-156.
38. Gaitán-Cepeda LA, Martínez-González M, Ceballos-Salobreña A (2005). Oral candidosis as a clinical marker of immune failure in patients with HIV/AIDS on HAART. AIDS Patient Care STDS 19: 70-77.
39. Giacaman RA, Nobbs AH, Ross KF, Herzberg MC (2007). Porphyromonas gingivalis selectively up-regulates the HIV-1 coreceptor CCR5 in oral keratinocytes. J Immunol 179: 2542-2550.
40. Glick M, Muzyka BC, Lurie D, Salkin LM (1994a). Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol 77: 344-349.
41. Glick M, Muzyka BC, Salkin LM, Lurie D (1994b). Necrotizing ulcerative periodontitis: a marker for immune deterioration and a predictor for the diagnosis of AIDS. J Periodontol 65: 393-397.
42. Gonçalves de Souza L, Souto R, Colombo AP (2009). Detection of Helicobacter pylori, Enterococcus faecalis, and Pseudomonas aeruginosa in the subgingival biofilm of HIV-infected subjects undergoing HAART with chronic periodontitis. Eur J Clin Microbiol Infect Dis 28: 1335-1342.
43. Gonçalves de Souza L, Ferreira SM, Silva A Jr et al (2004). Association of T CD4 lymphocyte levels and subgingival microbiota of chronic periodontitis in HIV-infected Brazilians under HAART. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97: 196-203.
44. Gonçalves de Souza L, Soares Ferreira SM, Souza CO, Souto R, Colombo AP (2007). Clinical and microbiological profiles of human immunodeficiency virus (HIV)-seropositive Brazilians undergoing highly active antiretroviral therapy and HIV-seronegative Brazilians with chronic periodontitis. J Periodontol 78: 87-96.
45. González OA, Ebersole JL, Huang CB (2009). Oral infectious diseases: a potential risk factor for HIV virus recrudescence? Oral Dis 15: 313-327.
46. Goto Y, Yeh CK, Notkins AL, Prabhakar BS (1991). Detection of proviral sequences in saliva of patients infected with human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 7: 343-347.
47. Greenspan J, Greenspan D (2008). Oral complications in HIV infection. In: Volberding PA, Sande MA, Lange J, Greene WC, eds Global HIV/AIDS medicine. WC. Saunders, Elsevier B.V. Inc. Publishing: Philadephia, USA, pp. 215-225.
48. Greenspan D, Gange SJ, Phelan JA et al (2004). Incidence of oral lesions in HIV-1-infected women: reduction with HAART. J Dent Res 83: 145-150.
49. Groot F, Sanders RW, Ter Brake O et al (2006). Histatin 5-derived peptide with improved fungicidal properties enhances human immunodeficiency virus type 1 replication by promoting viral entry. J Virol 80: 9236-9243.
50. Habte HH, Mall AS, De Beer C, Lotz ZE, Kahn D (2006). The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay. Virol J 3: 99. dol: .
51. Holtzer CD, Jacobson MA, Hadley WK et al (1998). Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994-1997. AIDS 12: 1931-1933.
52. Imai K, Ochiai K, Okamoto T (2009). Reactivation of latent HIV-1 infection by the periodontopathic bacterium Porphyromonas gingivalis involves histone modification. J Immunol 182: 3688-3695.
53. Jabra-Rizk MA, Falkler WA Jr, Enwonwu CO, Onwujekwe DI Jr, Merz WG, Meiller TF (2001). Prevalence of yeast among children in Nigeria and the United States. Oral Microbiol Immunol 16: 383-385.
54. Jameson B, Baribaud F, Pöhlmann S et al (2002). Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol 76: 1866-1875.
55. Jotwani R, Cutler CW (2003). Multiple dendritic cell (DC) subpopulations in human gingiva and association of mature DCs with CD4 + T-cells in situ. J Dent Res 82: 736-741.
56. Jotwani R, Palucka AK, Al-Quotub M et al (2001). Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies. J Immunol 167: 4693-4700.
57. Jotwani R, Muthukuru M, Cutler CW (2004). Increase in HIV receptors/co-receptors/alpha-defensins in inflamed human gingiva. J Dent Res 83: 371-377.
58. Khongkunthian P, Grote M, Isaratanan W, Piyaworawong S, Reichart PA (2001). Oral manifestations in 45 HIV-positive children from Northern Thailand. J Oral Pathol Med 30: 549-552.
59. Kim JS, Nag P, Landay AL et al (2006). Saliva can mediate HIV-1-specific antibody-dependent cell-mediated cytotoxicity. FEMS Immunol Med Microbiol 48: 267-273.
60. Klein RS, Phelan JA, Freeman K et al (1988). Low occupational risk of human immunodeficiency virus infection among dental professionals. N Engl J Med 318: 86-90.
61. Kroidl A, Schaeben A, Oette M, Wettstein M, Herfordt A, Häussinger D (2005). Prevalence of oral lesions and periodontal diseases in HIV-infected patients on antiretroviral therapy. Eur J Med Res 10: 448-453.
62. Kuboniwa M, Hendrickson EL, Xia Q et al (2009). Proteomics of Porphyromonas gingivalis within a model oral microbial community. BMC Microbiol 9: 98. dol: .
63. Lamster IB, Novak MJ (1992). Host mediators in gingival crevicular fluid: implications for the pathogenesis of periodontal disease. Crit Rev Oral Biol Med 3: 31-60.
64. Lamster IB, Grbic JT, Bucklan RS, Mitchell-Lewis D, Reynolds HS, Zambon JJ (1997). Epidemiology and diagnosis of HIV-associated periodontal diseases. Oral Disl 1: S141-S148.
65. Laskaris G, Hadjivassiliou M, Stratigos J (1992). Oral signs and symptoms in 160 Greek HIV-infected patients. J Oral Pathol Med 21: 120-123.
66. Leibur E, Tuhkanen A, Pintson U, Söder PO (1999). Prostaglandin E2 levels in blood plasma and in crevicular fluid of advanced periodontitis patients before and after surgical therapy. Oral Dis 5: 223-228.
67. Levy JA, Greenspan D (1988). HIV in saliva. Lancet 2: 1248.
68. Lin AL, Johnson DA, Sims CA, Stephan KT, Yeh CK (2006). Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102: 318-324.
69. Mackewicz CE, Yuan J, Tran P et al (2003). alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 17: F23-F32.
70. Margiotta V, Campisi G, Mancuso S, Accurso V, Abbadessa V (1999). HIV infection: oral lesions, CD4 + cell count and viral load in an Italian study population. J Oral Pathol Med 28: 173-177.
71. Masouredis CM, Katz MH, Greenspan D et al (1992). Prevalence of HIV-associated periodontitis and gingivitis in HIV-infected patients attending an AIDS clinic. J Acquir Immune Defic Syndr 5: 479-483.
72. Maticic M, Poljak M, Kramar B et al (2000). Proviral HIV-1 DNA in gingival crevicular fluid of HIV-1-infected patients in various stages of HIV disease. J Dent Res 79: 1496-1501.
73. Mok HP, Lever A (2008). Waking up the sleepers: HIV latency and reactivation. J Formos Med Assoc 107: 909-914.
74. Moore LV, Moore WE, Riley C, Brooks CN, Burmeister JA, Smibert RM (1993). Periodontal microflora of HIV positive subjects with gingivitis or adult periodontitis. J Periodontol 64: 48-56.
75. Moore JS, Rahemtulla F, Kent LW et al (2003). Oral epithelial cells are susceptible to cell-free and cell-associated HIV-1 infection in vitro. Virology 313: 343-353.
76. Murdoch DM, Venter WD, Van Rie A, Feldman C (2007). Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 4: 9.
77. Murray PA (1994). Periodontal diseases in patients infected by human immunodeficiency virus. Periodontol 2000(6): 50-67.
78. Murray PA, Grassi M, Winkler JR (1989). The microbiology of HIV-associated periodontal lesions. J Clin Periodontol 16: 636-642.
79. Nakashima H, Yamamoto N, Masuda M, Fujii N (1993). Defensins inhibit HIV replication in vitro. AIDS 7: 1129.
80. Nakou M, Kamma J, Gargalianos P, Laskaris G, Mitsis F (1997). Periodontal microflora of HIV infected patients with periodontitis. Anaerobe 3: 97-102.
81. Nicolatou-Galitis O, Velegraki A, Paikos S et al (2004). Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. Oral Dis 10: 145-150.
82. O'Shea S, Cordery M, Barrett WY, Richman DD, Bradbeer C, Banatvala JE (1990). HIV excretion patterns and specific antibody responses in body fluids. J Med Virol 31: 291-296.
83. Palella FJ Jr, Delaney KM, Moorman AC et al (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
84. Parveen Z, Acheampong E, Pomerantz RJ, Jacobson JM, Wigdahl B, Mukhtar M (2007). Effects of highly active antiretroviral therapy on HIV-1-associated oral complications. Curr HIV Res 5: 281-292.
85. Paster BJ, Russell MK, Alpagot T et al (2002). Bacterial diversity in necrotizing ulcerative periodontitis in HIV-positive subjects. Ann Periodontol 7: 8-16.
86. Patel M, Coogan M, Galpin JS (2003). Periodontal pathogens in subgingival plaque of HIV-positive subjects with chronic periodontitis. Oral Microbiol Immunol 18: 199-201.
87. Patton LL (2000). Sensitivity, specificity, and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90: 182-188.
88. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr (2000). Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89: 299-304.
89. Paul S, Gilbert HM, Lande L et al (2002). Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001. AIDS Res Hum Retroviruses 18: 501-506.
90. Pinheiro A, Marcenes W, Zakrzewska JM, Robinson PG (2004). Dental and oral lesions in HIV infected patients: a study in Brazil. Int Dent J 54: 131-137.
91. Quiñones-Mateu ME, Lederman MM, Feng Z et al (2003). Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 17: F39-F48.
92. Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, González-Ramírez I, Ponce-de-León S (2003). The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1, 000 consecutive patients: aA 12-year study in a referral center in Mexico. Medicine (Baltimore) 82: 39-50.
93. Ramírez-Amador V, Ponce-de-León S, Anaya-Saavedra G, Crabtree Ramírez B, Sierra-Madero J (2007). Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City. Clin Infect Dis 45: 925-932.
94. Ramos-Gomez FJ, Flaitz C, Catapano P, Murray P, Milnes AR, Dorenbaum A (1999). Classification, diagnostic criteria, and treatment recommendations for orofacial manifestations in HIV-infected pediatric patients. Collaborative Workgroup on Oral Manifestations of Pediatric HIV Infection. J Clin Pediatr Dent 23: 85-96.
95. Ranganathan K, Umadevi M, Saraswathi TR, Kumarasamy N, Solomon S, Johnson N (2004). Oral lesions and conditions associated with human immunodeficiency virus infection in 1000 South Indian patients. Ann Acad Med Singapore 33(Suppl.): 37-42.
96. Reichart PA, Khongkhunthian P, Bendick C (2003). Oral manifestations in HIV-infected individuals from Thailand and Cambodia. Med Microbiol Immunol 192: 157-160.
97. Reznik DA (2006). Oral manifestations of HIV disease. Top HIV Med 2005(13): 143-148.
98. Robinson PG (2002). The significance and management of periodontal lesions in HIV infection. Oral Dis 8(Suppl.): 91-97.
99. Rodríguez-Iñigo E, Jiménez E, Bartolomé J et al (2005). Detection of human immunodeficiency virus type 1 RNA by in situ hybridization in oral mucosa epithelial cells from anti-HIV-1 positive patients. J Med Virol 77: 17-22.
100. Rohr O, Marban C, Aunis D, Schaeffer E (2003). Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol 74: 736-749.
101. Santos LC, Castro GF, De Souza IP, Oliveira RH (2001). Oral manifestations related to immunosuppression degree in HIV-positive children. Braz Dent 12: 135-138.
102. Sanz M, Fernandez JL, Carasol M et al (1996). Detection of HIV virus in saliva and gingival crevicular fluid. Its correlation with periodontal statusand AIDS symptomatology (abstract). J Dent Res 75(Spec Iss): 156.
103. Schmidt-Westhausen AM, Priepke F, Bergmann FJ, Reichart PA (2000). Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med 29: 336-341.
104. Schrager LK, D'Souza MP (1998). Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280: 67-71.
105. Schuman P, Ohmit SE, Sobel JD et al (1998). Oral lesions among women living with or at risk for HIV infection. HIV Epidemiology Research Study (HERS) Group. Am J Med 104: 559-564.
106. Scully C, Porter SR, Mutlu S, Epstein JB, Glover S, Kumar N (1999). Periodontopathic bacteria in English HIV-seropositive persons. AIDS Patient Care STDS 13: 369-374.
107. Shangase L, Feller L, Blignaut E (2004). Necrotising ulcerative gingivitis/periodontitis as indicators of HIV-infection. SADJ 59: 105-108.
108. Shugars DC, Alexander AL, Fu K, Freel SA (1999). Endogenous salivary inhibitors of human immunodeficiency virus. Arch Oral Biol 44: 445-453.
109. Shugars DC, Patton LL, Freel SA et al (2001). Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva. J Dent Res 80: 414-420.
110. Spear GT, Alves ME, Cohen MH, Bremer J, Landay AL (2005). Relationship of HIV RNA and cytokines in saliva from HIV-infected individuals. FEMS Immunol Med Microbiol 45: 129-136.
111. Tappuni AR, Fleming GJ (2001). The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92: 623-628.
112. Teanpaisan R, Douglas CW, Nittayananta W (2001). Isolation and genotyping of black-pigmented anaerobes from periodontal sites of HIV-positive and non-infected subjects in Thailand. J Clin Periodontol 28: 311-318.
113. Tenenbaum H, Elkaim R, Cuisinier F, Dahan M, Zamanian P, Lang JM (1997). Prevalence of six periodontal pathogens detected by DNA probe method in HIV vs non-HIV periodontitis. Oral Dis 3(Suppl.): S153-S155.
114. Tsang CS, Samaranayake LP (2001). Predominant cultivable subgingival microbiota of healthy and HIV-infected ethnic Chinese. APMIS 109: 117-126.
115. Tukutuku K, Muyembe-Tamfum L, Kayembe K, Mavuemba T, Sangua N, Sekele I (1990). Prevalence of dental caries, gingivitis, and oral hygiene in hospitalized AIDS cases in Kinshasa, Zaire. J Oral Pathol Med 19: 271-272.
116. Turville SG, Cameron PU, Arthos J et al (2001). Bitter-sweet symphony: defining the role of dendritic cell gp120 receptors in HIV infection. J Clin Virol 22: 229-239.
117. UNAIDS (2008). Joint United Nations Programme on HIV/AIDS. 2008 report on the global AIDS epidemic: Accessed August 26, 2009.
118. Van Dyke TE, Serhan CN (2003). Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 82: 82-90.
119. Van Kooyk Y, Engering A, Lekkerkerker AN, Ludwig IS, Geijtenbeek TB (2004). Pathogens use carbohydrates to escape immunity induced by dendritic cells. Curr Opin Immunol 16: 488-493.
120. Williams SA, Greene WC (2007). Regulation of HIV-1 latency by T-cell activation. Cytokine 39: 63-74.
121. Winkler JR, Robertson PB (1992). Periodontal disease associated with HIV infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 73: 145-150.
122. Xie H, Belogortseva NI, Wu J, Lai WH, Chen CH (2006). Inhibition of human immunodeficiency virus type 1 entry by a binding domain of Porphyromonas gingivalis gingipain. Antimicrob Agents Chemother 50: 3070-3074.
123. Yeung SC, Stewart GJ, Cooper DA, Sindhusake D (1993a). Progression of periodontal disease in HIV seropositive patients. J Periodontol 64: 651-657.
124. Yeung SC, Kazazi F, Randle CG et al (1993b). Patients infected with human immunodeficiency virus type 1 have low levels of virus in saliva even in the presence of periodontal disease. J Infect Dis 167: 803-809.
125. Zambon JJ, Reynolds HS, Genco RJ (1990). Studies of the subgingival microflora in patients with acquired immunodeficiency syndrome. J Periodontol 61: 699-704.
126. Zhang L, Yu W, He T et al (2002). Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298: 995-1000.